Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Non-Current Assets: 2023-2024

Historic Non-Current Assets for Zenas BioPharma (ZBIO) over the last 2 years, with Dec 2024 value amounting to $14.0 million.

  • Zenas BioPharma's Non-Current Assets rose 162.85% to $25.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.4 million, marking a year-over-year increase of 162.85%. This contributed to the annual value of $14.0 million for FY2024, which is 67.68% up from last year.
  • As of FY2024, Zenas BioPharma's Non-Current Assets stood at $14.0 million, which was up 67.68% from $8.4 million recorded in FY2023.
  • Zenas BioPharma's Non-Current Assets' 5-year high stood at $14.0 million during FY2024, with a 5-year trough of $8.4 million in FY2023.
  • Its 2-year average for Non-Current Assets is $11.2 million, with a median of $11.2 million in 2023.
  • Data for Zenas BioPharma's Non-Current Assets shows a peak YoY soared of 67.68% (in 2024) over the last 5 years.
  • Zenas BioPharma's Non-Current Assets (Yearly) stood at $8.4 million in 2023, then skyrocketed by 67.68% to $14.0 million in 2024.